New biomarker can predict cancer prognosis and spread
Martha E. Hjelmeland, Jone Trovik and Camilla Krakstad are three of the researchers at the Women's Clinic at Haukeland University Hospital and the Bergen Research Group for Gynecological Cancer, who have discovered that the loss of vimentin, a protein, in preoperative biopsies can predict poor prognosis and lymph node metastasis in patients with endometrial cancer.
Hovedinnhold
The study, which included 1483 patients from 14 European hospitals, showed that patients with low levels of vimentin had a higher risk of aggressive disease and poorer survival.
This discovery can improve risk classification and treatment decisions for endometrial cancer patients. By including vimentin as a clinical marker, doctors can better identify patients at high risk for recurrence and metastasis, leading to more targeted and effective treatment. This can potentially reduce the need for extensive surgical procedures and improve patients' quality of life.
Information about Bergen Gynecologic Cancer Research Group | University of Bergen and Haukeland University Hospital
The text is generated by Artificial Intelligence.
